» Articles » PMID: 16234399

Surveillance for Isocyanate Asthma: a Model Based Cost Effectiveness Analysis

Overview
Date 2005 Oct 20
PMID 16234399
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Aims: Because logistical and financial obstacles impede using large prospective cohort studies, surveillance decisions in occupational settings must often be made without evidence of relative benefits and costs. Using the example of isocyanate induced asthma, the most commonly reported immune mediated occupational asthma, the authors developed a model based approach to evaluate the costs and benefits of surveillance from both an employer and a societal perspective.

Methods: The authors used a mathematical simulation model of isocyanate asthma to compare annual surveillance to passive case finding. Outcome measures included symptom free days (SFD), quality adjusted life years (QALY), direct costs, productivity losses, and incremental cost effectiveness ratio (CER), measured from the employer and the societal perspectives. Input data were obtained from a variety of published sources.

Results: For 100,000 exposed workers, surveillance resulted in 683 fewer cases of disability over 10 years. Surveillance conferred benefits at an incremental cost of 24,000 dollars/QALY (employer perspective; 13.33 dollars/SFD) and was cost saving from the societal perspective. Results were sensitive to assumptions about sensitisation rate, removal rates, and time to diagnosis, but not to assumptions about therapy costs and disability rates.

Conclusions: Baseline results placed the CER for surveillance for isocyanate asthma within the acceptable range. Costs from the societal and employer perspective differed substantially with a more attractive CER from the societal perspective, suggesting opportunities for employer/societal cost sharing. The analysis demonstrates the value of a model based approach to evaluate the cost effectiveness of surveillance programmes for isocyanate asthma, and to inform shared decision making among clinicians, patients, employers, and society. Such a modeling approach may be applicable to surveillance programmes for other work related conditions.

Citing Articles

A Comprehensive Review of Occupational Medicine in the Paint Industry: Roles of Family Medicine and Internal Medicine.

Jogie J Cureus. 2025; 17(1):e76970.

PMID: 39912028 PMC: 11793994. DOI: 10.7759/cureus.76970.


The Relationships Between Control Measures and Absenteeism in the Context of Internal Control.

Bayram M, Burgazoglu H Saf Health Work. 2020; 11(4):443-449.

PMID: 33329910 PMC: 7728821. DOI: 10.1016/j.shaw.2020.07.007.


Opportunities and obstacles in translating evidence to policy in occupational asthma.

Tarlo S, Arif A, Delclos G, Henneberger P, Patel J Ann Epidemiol. 2017; 28(6):392-400.

PMID: 28434545 PMC: 5953844. DOI: 10.1016/j.annepidem.2017.03.002.


Identification of novel reaction products of methylene-bis-phenylisocyanate ("MDI") with oxidized glutathione in aqueous solution and also during incubation of MDI with a murine hepatic S9 fraction.

Wisnewski A, Liu J, Nassar A Toxicol In Vitro. 2016; 36:97-104.

PMID: 27453132 PMC: 5010927. DOI: 10.1016/j.tiv.2016.07.011.


Economic Evaluations of Public Health Surveillance Systems: a Systematic Review.

Herida M, Dervaux B, Desenclos J Eur J Public Health. 2016; 26(4):674-80.

PMID: 26850905 PMC: 7108512. DOI: 10.1093/eurpub/ckv250.


References
1.
Wheeler S, Rosenstock L, Barnhart S . A case series of 71 patients referred to a hospital-based occupational and environmental medicine clinic for occupational asthma. West J Med. 1998; 168(2):98-104. PMC: 1304837. View

2.
Milton D, Solomon G, Rosiello R, Herrick R . Risk and incidence of asthma attributable to occupational exposure among HMO members. Am J Ind Med. 1997; 33(1):1-10. DOI: 10.1002/(sici)1097-0274(199801)33:1<1::aid-ajim1>3.0.co;2-2. View

3.
Perfetti L, Cartier A, Ghezzo H, Gautrin D, Malo J . Follow-up of occupational asthma after removal from or diminution of exposure to the responsible agent: relevance of the length of the interval from cessation of exposure. Chest. 1998; 114(2):398-403. DOI: 10.1378/chest.114.2.398. View

4.
Ross D, McDonald J . Health and employment after a diagnosis of occupational asthma: a descriptive study. Occup Med (Lond). 1998; 48(4):219-25. DOI: 10.1093/occmed/48.4.219. View

5.
Baur X, Stahlkopf H, Merget R . Prevention of occupational asthma including medical surveillance. Am J Ind Med. 1998; 34(6):632-9. DOI: 10.1002/(sici)1097-0274(199812)34:6<632::aid-ajim13>3.0.co;2-n. View